A global diversified healthcare company operating across medical devices, diagnostics, nutritional products, and international branded pharmaceuticals has demonstrated a consistent and credible commitment to dividend growth, posting a 7% 3-year dividend compound annual growth rate (CAGR). That growth rate ranks in the top 40% of all dividend-paying stocks, and it is the result of a business that generates substantial recurring cash flows across segments spanning continuous glucose monitoring devices, cardiac rhythm management products, point-of-care diagnostics systems, and consumer nutrition formulas. The company has raised its dividend for more than 50 consecutive years — one of the longest active streaks in the healthcare sector — reflecting a culture of capital discipline and shareholder prioritization that has survived multiple economic cycles.
The medical devices segment has emerged as the primary growth engine, delivering 10.5% sales growth in its most recent fiscal year, driven by innovation in wearable glucose monitoring systems and electrophysiology solutions. Meanwhile, the diagnostics division navigated a post-pandemic normalization in testing demand, and the nutrition business faced near-term headwinds from manufacturing cost pressures and competitive share dynamics. These are real challenges, but they exist alongside a balance sheet that carries net leverage of just 0.4x — far below the industry average of 1.7x — and a forward earnings per share (EPS) growth outlook of 10%. The combination of innovation strength, financial conservatism, and a multi-decade dividend track record creates a durable total-return profile that goes well beyond yield alone.
This stock was selected for an increased position in the Dividend Growth Stocks Portfolio because its 7% 3-year dividend CAGR, robust analyst target upside of 27.5%, and a 50+ year increase streak collectively reinforce the kind of compounding dividend growth discipline this portfolio is built around. Within a portfolio designed to identify healthcare innovators and other quality dividend growers with sustainable trajectories, this name continues to demonstrate why it belongs — and why enlarging the position is a conviction-backed decision.
